Adult stem cells

Pharma

Stem cell company Athersys eyes potential new opportunities for its stroke therapy in Japan

Athersys (NYSE:ATHX) is looking to Japan for potential opportunities to bring its MultiStem therapies to market quicker. In its annual financial results call on Thursday, Athersys’ chief operating officer, BJ Lehmann, explained that legislation passed last fall in Japan could allow for conditional approval of new regenerative medicines that demonstrate strong safety profiles in clinical […]

presented by